mortality/aging
• 10 to 14 days after pIpC treatment
|
hematopoietic system
• aplasia in pIpC-treated mice
|
• reduced frequencies and total number in the bone marrow of pIpC-treated mice
|
• in pIpC-treated mice
|
• reduced frequencies and total number in the bone marrow of pIpC-treated mice
|
• reduced frequencies and total number in the bone marrow of pIpC-treated mice
|
• in pIpC-treated mice
|
• in pIpC-treated mice
|
• in pIpC-treated mice
|
• in pIpC-treated mice
|
• in pIpC-treated mice
|
• decreased frequency and absolute numbers of LSK and long-term hematopoietic stem cells, short-term hematopoietic stem cells, and multipotent progenitors in the bone marrow of pIpC-treated mice
|
pancytopenia
(
J:308564
)
• in pIpC-treated mice
|
• impaired repopulation capacity of hematopoietic stem cells with increased cell death and DNA damage in pIpC-treated mice
|
• cell autonomous, primary and in bone marrow transplantation experiments, in pIpC-treated mice
|
immune system
• in pIpC-treated mice
|
• in pIpC-treated mice
|
• cell autonomous, primary and in bone marrow transplantation experiments, in pIpC-treated mice
|